I karcinogenicitetsforsøg med peroral risperidon til rotter og mus blev der set en stigning i hypofyseadenomer (mus), endokrine pankreasadenomer (rotter) og mammakirteladenomer (begge arter).
In oral carcinogenicity studies of risperidone in rats and mice, increases in pituitary gland adenomas (mouse), endocrine pancreas adenomas (rat), and mammary gland adenomas (both species) were seen.